Member Info for Mars1

Thought the vmarket interview raised an interesting point on NXP001 Dan said they have some interesting commercial updates to provide with plenty of upside. The regulatory issue seems to be holding back any announcement so hopefully soon.

Surely if google adds has a bids SDK they can direct the adds as with any other game maker

Imagine how small the research facility could be at GSK or any pharma to reengineer all their out of patent stars and future proof them

Everyone focuses on the value of the drugs but the cocrystal technology providing the mechanism to evolve so many drugs has to have a value in its own right

Operating costs covered by Ebers, placing covers development costs of 02 and 04, all the cash incoming will be used for what?

In the podcast Dan said there was £3m due now on NXP001 plus ano £3.5m for a joint venture in China plus money coming in from Ebers and close on NXP002. The co is only valued at £44m.

Surprised where this is given the prospective revenue on its way. For the first time in the RNS negotiations are not just in Asia for NXP002 but are also in the US, so potentially global liscensing will be in place before the final clinical trial is complete.

Fantastic podcast lots to come Dr Dan excited about the commercial updates that are on their way re NXP001, talking to several possible partners re NXP002 plus tons of other progress

y0g1 may be understated if £6m 2nd half it was earned in 21/2months puts annualised revenue at £28.8m on a historic basis one would expect this to grow as more parties come fully on stream yabadaba

This is comment in RNS is interesting as it suggests running costs are covered cash raised is purely for product development
“ Income from Ebers-related activities continues to support Nuformix's low operating costs. ”

Thanks I have a fantastic imagination however it is not required here all that is happening is real

Nothing wrong with the last RNS
“ It confirms that the Company is in discussion with multiple potential licensees in Japan and Asia, including but not limited to its NXP002 programme.”

Sorry preemptive spelling think it was Croz.

Aim agree it is when the tone of the posting changes we saw this morning from Crotch to suit their trading to talk down a share.

Traders back trying to force price down

China pharma news is all about cancer
https://www.cphi.com/china/visit/news-and-updates/china-pharma-trends-and-news

When news comes PIs will not be able to buy even if seller is around MMs will feed IIs first it will be NT and fill/kill only

PS look up Michael Reynolds and he comes up as working at Merrills
https://www.linkedin.com/in/michael-reynolds-ca-sa-cfa-09848636?originalSubdomain=uk

Y see link
https://angel.co/company/ebers-tech

Not a side line when CBDs can help so many with ms and epilepsy and more. More mainstream for those in need however No2 has the attention of Asia And Japan